Your browser doesn't support javascript.
loading
Calculating variant penetrance from family history of disease and average family size in population-scale data.
Spargo, Thomas P; Opie-Martin, Sarah; Bowles, Harry; Lewis, Cathryn M; Iacoangeli, Alfredo; Al-Chalabi, Ammar.
Affiliation
  • Spargo TP; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.
  • Opie-Martin S; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.
  • Bowles H; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.
  • Lewis CM; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, de Crespigny Park, London, SE5 8AF, UK.
  • Iacoangeli A; Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • Al-Chalabi A; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK. alfredo.iacoangeli@kcl.ac.uk.
Genome Med ; 14(1): 141, 2022 12 15.
Article in En | MEDLINE | ID: mdl-36522764
ABSTRACT

BACKGROUND:

Genetic penetrance is the probability of a phenotype when harbouring a particular pathogenic variant. Accurate penetrance estimates are important across biomedical fields including genetic counselling, disease research, and gene therapy. However, existing approaches for penetrance estimation require, for instance, large family pedigrees or availability of large databases of people affected and not affected by a disease.

METHODS:

We present a method for penetrance estimation in autosomal dominant phenotypes. It examines the distribution of a variant among people affected (cases) and unaffected (controls) by a phenotype within population-scale data and can be operated using cases only by considering family disease history. It is validated through simulation studies and candidate variant-disease case studies.

RESULTS:

Our method yields penetrance estimates which align with those obtained via existing approaches in the Parkinson's disease LRRK2 gene and pulmonary arterial hypertension BMPR2 gene case studies. In the amyotrophic lateral sclerosis case studies, examining penetrance for variants in the SOD1 and C9orf72 genes, we make novel penetrance estimates which correspond closely to understanding of the disease.

CONCLUSIONS:

The present approach broadens the spectrum of traits for which reliable penetrance estimates can be obtained. It has substantial utility for facilitating the characterisation of disease risks associated with rare variants with an autosomal dominant inheritance pattern. The yielded estimates avoid any kinship-specific effects and can circumvent ascertainment biases common when sampling rare variants among control populations.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Amyotrophic Lateral Sclerosis Limits: Humans Language: En Journal: Genome Med Year: 2022 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Main subject: Amyotrophic Lateral Sclerosis Limits: Humans Language: En Journal: Genome Med Year: 2022 Type: Article Affiliation country: United kingdom